1.1Death receptor activation
An agonist antibody clusters death receptor 5 at the tumor cell surface. The receptor complex recruits and activates caspase-8, which activates executioner caspases in responsive cells.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An agonist antibody clusters death receptor 5 at the tumor cell surface. The receptor complex recruits and activates caspase-8, which activates executioner caspases in responsive cells.
A small molecule blocks the chymotrypsin-like catalytic site of the proteasome. The resulting accumulation of undegraded proteins increases proteotoxic stress and triggers apoptosis in responsive tumor cells.
Autologous T cells express a chimeric receptor that binds a surface antigen on malignant cells. Receptor engagement triggers the release of perforin and granzymes, which initiate target-cell death.
Intracellular kinases convert the analog to a nucleotide triphosphate. DNA polymerases incorporate it into nascent DNA, which impairs strand elongation and stalls replication.
In leukemia driven by the BCR–ABL fusion kinase, a small molecule occupies the kinase ATP-binding site and reduces substrate phosphorylation. The reduction in kinase signaling suppresses proliferation of cells that depend on the fusion protein.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary diagnostic laboratory distributes viable cells from a canine lymphoma aspirate across microplate wells. Separate wells receive vehicle, a PRMT5 inhibitor, a BCL-2 family inhibitor, or both inhibitors. The laboratory measures viable cell counts and caspase activity and reports each treatment condition relative to the vehicle control.
A direct MCL-1 inhibitor occupies the BCL-2 family inhibitor position in the pair. Its binding site is the BH3-binding groove of MCL-1, where it displaces proapoptotic binding partners. A cell assay compares the pair with both single-agent conditions and measures symmetric dimethylarginine as a PRMT5 activity readout and cleaved caspase-3 as an apoptosis readout.
A microplate assay exposes tumor cells to the inhibitors using three schedules. Both inhibitors start at 0 hours in the simultaneous arm, while the sequential arms start one inhibitor at 0 hours and add the other at 24 hours in opposite orders. The first inhibitor stays in the well after the second is added. All arms use the same final concentrations and record viability at 72 hours.
A patient-derived tumor organoid system holds size-matched organoids in an extracellular matrix in a multiwell plate. Replicate wells receive vehicle, either inhibitor alone, or the paired inhibitors through the culture medium. Live imaging tracks changes in organoid area, and an endpoint stain measures the fraction of cells positive for cleaved caspase-3.
A microfluidic culture device holds tumor spheroids in parallel chambers supplied by independently controlled perfusion channels. The channels deliver vehicle, either inhibitor alone, or both inhibitors at matched flow rates. Time-lapse microscopy records spheroid growth during exposure, and an endpoint fluorescent stain measures cell death within each chamber.
An orally administered small molecule occupies the BH3-binding groove of BCL-2. It displaces sequestered proapoptotic proteins and promotes mitochondrial outer membrane permeabilization in BCL-2-dependent cells.
A small molecule competes with S-adenosylmethionine for the cofactor-binding pocket of PRMT5 in the PRMT5–MEP50 complex. Reduced catalytic activity lowers symmetric dimethylarginine formation on protein substrates.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The invention includes a method of treating an ErbB family phospho Y240 PTEN positive tumor in a mammal comprising administering a src family targeted tyrosine kinase inhibitor, followed by or in combination with treatment with an ErbB family targeted tyrosine kinase inhibitor.A · US 2012/0165340 A1 · ¶ 46
In some embodiments, methods of treating an RMT-mediated disorder in a subject are provided which comprise administering an effective amount of a compound described herein (e.g., a compound of Formula (I)), or a pharmaceutically acceptable salt thereof), to a subject in need of treatment. In certain embodiments, the effective amount is a therapeutically effective amount.B · US 2020/0289469 A1 · ¶ 177
An empty cell means only that no passage was reproduced there.
Methods for sensitizing tumors to inhibition and targeted therapy by modulating PTEN phosphorylation are provided.A · US 2012/0165340 A1 · ¶ 1
This complicates the significance of detecting wild type PTEN in tumor cells, as it is not necessarily an indication that PTEN function has been retained.A · US 2012/0165340 A1 · ¶ 7
Thus, there is a need for the development of small molecules that are capable of inhibiting the activity of arginine methyltransferases.B · US 2020/0289469 A1 · ¶ 4
Thus, such methods encompass inhibition of RMT activity both in vitro and in vivo.B · US 2020/0289469 A1 · ¶ 7
patent.fyi, US 2026/0355188 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355188/, SHA-256 250d70ed93b4987da63c86a4469aa3a2b74cca89d6a648facdb6fabec13db094